Cloudvec and Danaher Life Sciences Platform Forge Strategic Partnership to Advance High-Quality Development in Gene Delivery

Jointly Promote High-Quality Development in the Gene Delivery Industry

ShanghaiMay 30, 2023PR Newswire -- Recently, VectorBuilder (Guangzhou) Co., Ltd. ("VectorBuilder") and the Danaher Life Sciences platform held a signing ceremony for a strategic cooperation agreement. Based on their leading positions in the industry, advanced platforms and technical capabilities, and strong cooperative intentions, the two parties have reached a global strategic partnership to accelerate the high-quality development of the gene delivery industry.

VectorBuilder and Danaher Life Science Platform Strategic Signing Ceremony

This strategic cooperation will combine VectorBuilder's leading gene delivery technology and industry insights with Danaher's comprehensive process production solutions, which hold a competitive position in the life sciences sector. Together, they will develop and optimize preclinical and clinical production processes for several gene delivery vectors used in cell and gene therapy, including plasmids, lentiviruses, AAV, and LNP-mRNA. The collaboration will delve into areas such as scaling up production, process quality testing and control, and cost reduction and efficiency improvement. By working hand-in-hand, they aim to explore and establish industry-leading methods and processes, providing the sector with more research and development tools, complete solutions, and technical services. The ultimate goal is to comprehensively and systematically address the challenges and issues faced by the industry.

Dr. Lan Tian, Chief Scientist of VectorBuilder, stated that Danaher has leading advantages in products, technologies, and applications in the global life science field. VectorBuilder possesses rich technical experience and insights in gene delivery and gene drug research, development, and production. He expressed great anticipation for the deep collaboration between both parties to provide more and better products, technologies, and services in gene delivery, as well as more comprehensive one-stop solutions, for over 50,000 current and future scientific research and clinical users of the company. This collaboration aims to accelerate life science research, reduce costs, improve efficiency, and enhance the accessibility of gene drugs.

Li Lei, President of Danaher China Life Sciences Platform, stated that genetic science research and global cell and gene therapies are experiencing vigorous development, with an increasing number of gene therapies expected to be approved for marketing in the foreseeable future. VectorBuilder is an outstanding partner in the fields of gene delivery research and gene therapy industry. It is hoped that this collaboration will enhance both parties’ technical capabilities and management experience, while providing significant technological and production services and empowerment to customers and the industry.

After the signing ceremony, VectorBuilder and Danaher jointly organized a salon for the cell and gene therapy industry in the Guangdong-Hong Kong-Macao Greater Bay Area. Representatives from various parties, including the Health Commission, VectorBuilder, Danaher, Sun Yat-sen University Cancer Center, and industrial capital, engaged in enthusiastic discussions on the key bottlenecks faced by the region's cell and gene therapy industry ecosystem and ways to address them. The discussions focused on government-academia-enterprise cooperation and communication mechanisms, the improvement of IIT (investigator-initiated trial) systems, product introduction systems, innovation incentive systems, talent incentives, and other related topics.

Danaher Team Visits VectorBuilder Production Base

In the afternoon, Christopher Riley, Vice President of Danaher Corporation, and Li Lei, President of Danaher China's Life Science Platform, visited VectorBuilder's research and clinical R&D production base for exchange and discussion, further exploring process development and optimization upgrades in the gene delivery industry.